C-reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance

The goal of this study is to determine whether markers of vascular inflammation (such as c-reactive protein) can predict endothelial dysfunction (as measured by flow-mediated dilation) in postmenopausal women with glucose intolerance compared to normal controls.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glucose Intolerance Glucose Metabolism Disorders Hyperglycemia Metabolic Diseases Nutritional and Metabolic Diseases

Age range

40 year–65 year

Sex eligibility

Female

Study type

Observational

Primary location

Yale Center for Clinical Investigation

New Haven, Connecticut, 06520, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

healthy postmenopausal women
ages 40-65

Exclusion criteria

smokers
diabetes requiring medication

Treatment and study plan

Primary outcomes

c-reactive protein

Time frame: performed after screening evaluation

Secondary outcomes

flow-mediated dilation of brachial artery

Time frame: performed twice after screening visit
sex steroids

Time frame: performed after screening visit

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Yale University

Other

Registry information

Important dates

Study start: 2002
Primary completion: 2003
Study completion: 2008
First posted: Jan 9, 2008
Registry last updated: Apr 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed